with Phase 2 RELIEVE UCCD results from Sanofi/Teva’s duvakitug expected to spark discussions about potential future of this mechanism of action in IBD. As ECCO 2025 unfolds, all eyes will be on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback